Ürogenital Sistemde Enfeksiyona Yol Açan Bakteriler

Sparling PF. Bacterial virulence and pathogenesis: an overview. Rev Infect Dis 1983;5(Suppl 4):S637-46

Kunin CM. Urinary tract infections. Detection, prevention and management, ed 5. Baltimore, MD: Williams and Wilkins; 1997.

Ragnarsdottir B, Fischer H, Godaly G, et al. TLR- and CXCR1-dependent innate immunity: insights into the genetics of urinarytract infections. Eur J Clin Invest 2008;38(Suppl 2):12–20.

Cohn EB, Schaeffer AJ. Urinary tract infections in adults. ScientificWorldJournal 2004;4(Suppl 1):76–88.

Sedberry-Ross S, Pohl HG. Urinary tract infections in children. CurrUrol Rep 2008;9:165–71.

Agace WW, Hedges SR, Ceska M, Svanborg C. Interleukin-8 and theneutrophil response to mucosal gram-negative infection. J ClinInvest 1993;92:780–5

Koves B, Wullt B. The Roles of the Host and the Pathogens in Urinary Tract Infections. Eur Urol Suppl (2016)

Relman D, Falkow S. A molecular perspective of microbial pathogenicity. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell,Douglas, and Bennett’s Principles and Practice of Infectious Diseases, ed 7.. Philadelphia, PA: Churchill Livingstone/Elsevier; 2009

Hacker J, Bender L, Ott M, et al. Deletions of chromosomal regions coding for fimbriae and hemolysins occur in vitro and in vivo in various extraintestinal Escherichia coli isolates. Microb Pathog1990;8:213–25

Johnson JR. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev 1991;4:80–128.

Roberts AP, Phillips R. Bacteria causing symptomatic urinary tract infection or asymptomatic bacteriuria. J ClinPathol 1979;32:492-6

Vosti KL, Goldberg LM, Monto AS, Rantz LA. Host481parasite interaction in patients with infections due to Escherichiacoli. I. The serogrouping of E. coli from intestinal and extraintestinal sources. J Clin Invest 1964;43:2377-858.

Griineberg RN. Relationship of infecting urinary organismsto the faecal flora in patients with symptomatic urinaryinfection. Lancet 1969;2:766-8

Brooks HJL, Benseman BA, Peck J, Bettelheim KA. Correlation between uropathogenic properties of Escherichia colifrom urinary tract infections and the antibody-coated bacteria test and comparison with faecal strains. J Hyg(Camb) 1981;87:53-61.

O'Grady F, Gauci CL, Watson BW,Hammond B. In vitro models simulating conditions of bacterial growth in theurinary tract. In: O'Grady F, Brumfitt W, eds. Urinary tract infection. London: Oxford University Press, 1968:80-92

Rocha H. Pathogenesis and clinicalmanagement of urinarytract infections. In: Kaye D, ed. Urinary tract infectionand its management. St Louis: CV Mosby, 1972:6-27

Hagberg L, Jodal U, Korhonen TK, Lidin-Janson G, Lindberg U, Svanborg-Ede´n C. Adhesion, hemagglutination, and virulence ofEscherichia coli causing urinary tract infections. Infect Immun1981;31:564–70

Kunin CM. Detection, prevention and management of urinary tract infections. A manual for the physician, nurse,and allied health worker. Philadelphia: Lea & Febiger,1972:1-55

Maskell R. The pathogenesis of urinary tract infection. In: Current topics in infection. 3. Urinary tract infection. NewYork: Elsevier Biomedical, 1982:6-20

Peerbooms PGH, Verweij AMJJ, MacLaren DM. Verocell invasiveness of Proteus mirabilis. Infect Immun 1984;43:1068-71

Leffler H, Svanborg-Ede´n C. Chemical identification of a glycosphingolipid receptor for Escherichia coli attaching to human urinary tract epithelial cells and agglutinating human erythrocytes.FEMS Microbiol Lett 1980;8:127–34.

Nowicki B, Svanborg-Ede´n C, Hull R, Hull S. Molecular analysis andepidemiology of the Dr hemagglutinin of uropathogenic Escherichia coli. Infect Immun 1989;57:446–51.

Walz W, Schmidt MA, Labigne-Roussel AF, Falkow S, Schoolnik G.AFA-I, a cloned afimbrial X-type adhesin from a human pyelonephritic Escherichia coli strain. Purification and chemical, functionaland serologic characterization. Eur J Biochem 1985;152:315–21.

Virkola R, Westerlund B, Holthofer H, Parkkinen J, Kekomaki M,Korhonen TK. Binding characteristics of Escherichia coli adhesins in human urinary bladder. Infect Immun 1988;56:2615–22.

Hovelius B, Mardh PA. Staphylococcussaprophyticus as a common cause of urinary tract infections. Rev Infect Dis 1984;6:328-37

Leffler H, Svanborg-Ede´n C. Glycolipid receptors for uropathogenicEscherichia coli on human erythrocytes and uroepithelial cells.Infect Immun 1981;34:920–9.

Plos K, Connell H, Jodal U, et al. Intestinal carriage of P fimbriatedEscherichia coli and the susceptibility to urinary tract infection inyoung children. J Infect Dis 1995;171:625–31.

Vaisanen V, Elo J, Tallgren LG, et al. Mannose-resistant aemagglutination and P antigen recognition are characteristic of Escherichiacoli causing primary pyelonephritis. Lancet 1981;2:1366–9

Wullt B, Bergsten G, Fischer H, et al. The host response to urinarytract infection. Infect Dis Clin North Am 2003;17:279–301.

Bergsten G, Samuelsson M, Wullt B, Leijonhufvud I, Fischer H,Svanborg C. PapG-dependent adherence breaks mucosal inertia

Hultgren SJ, Porter TN, Schaeffer AJ, Duncan JL. Role oftype 1 pili and effects of phase variation on lower urinary tract infections produced by Escherichia coli. Infect Immun 1985;50:370-7

Keith BR, Maurer L, Spears PA, Orndorff PE. Receptorbinding function of type 1 pili effects bladder colonization by a clinical isolate of Escherichia coli. Infect Immun 1986;53:693-6

Maayan MC, Ofek I, Medalia 0, Aronson M. Populationshift in mannose-specific fimbriated phase ofKlebsiella pneumoniae during experimental urinary tract infection in mice. Infect Immun 1985;49:785-9

Wright KJ, Seed PC, Hultgren SJ. Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili. Cell Microbiol 2007;9:2230–41.

Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. Intracellular bacterial biofilm-like pods in urinary tract infections.Science 2003;301:105–7

Connell I, Agace W, Klemm P, Schembri M, Marild S, Svanborg C. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc Natl Acad Sci U S A 1996;93:9827–32

Langermann S, Palaszynski S, Barnhart M, et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 1997;276:607–11.

Bouckaert J, Berglund J, Schembri M, et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol 2005;55:441–55.

Sharon N. Carbohydrates as future anti-adhesion drugs for infectious diseases. Biochim Biophys Acta 2006;1760:527–37.

Atkan ML, Beachey EH. Excretion of lipoteichoic acid by group A streptococci: influence of penicillin on excretion and loss of ability to adhere to human oral mucosal cells.J Clin Invest 1978;61:671-7

Chan RCY, Reid G, Irvin lIT, Bruce AW,Costerton JW. Competitive exclusion of uropathogens from human uroepithelial cells by Lactobacillus whole cells and cell wall fragments. Infect Immun 1985;47:84-9.

Berg HC. The rotary motor of bacterial flagella. Annu Rev Biochem 2003;72:19–54.

Lane MC, Alteri CJ, Smith SN, Mobley HL. Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract. Proc Natl Acad Sci U S A 2007;104:16669–74.

Dobrindt U, Hacker J. Uropathogens and virulence factors. In: Naber KG, Schaeffer AJ, Heyns CF, Matsumoto T, Shoskes DA, Bherklunc Johansen TE, editors. Urogenital Infections. Arnhem, The Netherlands: European Association of Urology; 2010. p. 4–22

Marrs CF, Zhang L, Foxman B. Escherichia coli mediated urinary tract infections: are there distinct uropathogenic E. coli (UPEC) pathotypes? FEMS Microbiol Lett 2005;252:183–90.

Koschinski A, Repp H, Unver B, et al. Why Escherichia coli alphahemolysin induces calcium oscillations in mammalian cells–thepore is on its own. FASEB J 2006;20:973–5. [33] Troeger H, Richter JF, Beutin L, et al. Escherichia coli alphahaemolysin induces focal leaks in colonic epithelium: a novel mechanism of bacterial translocation. Cell Microbiol 2007;9:2530–40.

Mabbett AN, Ulett GC, Watts RE, et al. Virulence properties of asymptomatic bacteriuria Escherichia coli. Int J Med Microbiol 2009;299:53–63. [35] Mills M, Meysick KC, O’Brien AD. Cytotoxic necrotizing factor typ 1 of uropathogenic Escherichia coli kills cultured human uroepithelial 5637 cells by an apoptotic mechanism. Infect Immun 2000;68: 5869–80.

Davis JM, Carvalho HM, Rasmussen SB, O’Brien AD. Cytotoxicnecrotizing factor type 1 delivered by outer membrane vesicles of uropathogenic Escherichia coli attenuates polymorphonuclear leukocyte antimicrobial activity and chemotaxis. Infect Immun 2006;74:4401–8

Tapiainen T, Hanni AM, Salo J, Ikaheimo I, Uhari M. Escherichia coliiofilm formation and recurrences of urinary tract infections in children. Eur J Clin Microbiol Infect Dis 2014;33:111–5.

Foxman B, Zhang L, Tallman P, et al. Virulence characteristics of Escherichia coli causing first urinary tract infection predict risk ofsecond infection. J Infect Dis 1995;172:1536–41.

Feldmann F, Sorsa LJ, Hildinger K, Schubert S. The salmochelin siderophore receptor IroN contributes to invasion of urothelial cells by extraintestinal pathogenic Escherichia coli in vitro. Infect Immun 2007;75:3183–7.

Brumbaugh AR, Smith SN, Subashchandrabose S, et al. Blocking yersiniabactin import attenuates extraintestinal pathogenic Escherichia coli in cystitis and pyelonephritis and represents a novel target to prevent urinary tract infection. Infect Immun 2015;83:1443–50.